Related Experiment Videos
Humanizing mice: catching up with elusive B1 receptors
Mark Connor1, Christopher W Vaughan
1Pain Management Research Institute, Kolling Institute, E25, Northern Clinical School, University of Sydney at Royal North Shore Hospital, St Leonards, 2065 NSW, Australia. markc@med.usyd.edu.au
British Journal of Pharmacology
|February 3, 2005
Summary
Researchers developed a humanized mouse model to study bradykinin B1 receptors and test a new nonpeptide antagonist for pain relief. This tool advances understanding of the kallikrein-kinin system in pain and inflammation.
Area of Science:
- Pharmacology
- Neuroscience
- Immunology
Background:
- Bradykinin receptor activation is crucial in inflammatory pain, with B1 receptors implicated in chronic pain conditions like arthritis and neuropathies.
- Studying B1 receptor function in vivo has been challenging due to the lack of nonpeptide antagonists and significant species variations between humans and rodents.
Purpose of the Study:
- To create a preclinical model for investigating human bradykinin B1 receptors in vivo.
- To evaluate the efficacy of a novel nonpeptide B1 receptor antagonist in a humanized mouse model.
Main Methods:
- Generation of a transgenic mouse model expressing the human B1 receptor gene.
- Administration of a novel nonpeptide B1 receptor antagonist.
- Assessment of acute and inflammatory nociception in the humanized mouse model.
Main Results:
- The developed humanized mouse model successfully allows for in vivo study of human B1 receptor function.
- The novel nonpeptide B1 receptor antagonist demonstrated effects on nociception in this model.
Conclusions:
- The humanized B1 receptor mouse provides a valuable tool for studying the kallikrein-kinin system.
- This model facilitates the development and testing of new therapeutic strategies targeting bradykinin B1 receptors for pain management.